Trucode is advancing in vivo gene editing applications for disorders including sickle cell disease that grew from Yale research and has been backed by GV and Kleiner Perkins.

Trucode Gene Repair, a US-based in-vivo gene editing technology company exploiting Yale University research, emerged out of stealth yesterday with $34m in funding co-led by venture firm Kleiner Perkins and GV, a corporate venturing arm of diversified conglomerate Alphabet. The round’s other investors were not disclosed, though representatives of metabolic disease drug developer Akero Therapeutics…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.